By Dr Roger Bosse

With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). T...

By Dr Xiaoqiu Wu and Dr Andrew P. Turnbull

Cellular RNAs play crucial roles during disease progression and represent a diverse and largely untapped class of biomolecules that can be exploite...

By Dr Megan M. MacBride

Genetically-engineered animal models (GEMs) are critical tools for drug discovery and development, but intellectual property (IP) concerns can comp...

By Dr Urban A. Kiernan and Dr Stephen Naylor

Technology was lauded as the saviour of the drug discovery and development (DDD) process during the late 1990s. A myriad of independent companies d...

By Abby Edwards and Dr Richard Massey

Human stem cells were once viewed primarily as regenerative materials for tissue repair through cell therapies. However, advances in technologies a...

By Dr Steffen Lawo and Dr Carlos le Sage

Research in drug discovery and biotechnology increasingly exploits gene editing at industrial scale in order to identify and validate new biologica...

By Dr Phil Jones

The mission at The University of Texas MD Anderson Cancer is to eradicate cancer, which remains a major cause of mortality worldwide. It is the sec...

By Dr Amy L. Roe and Dr Jonathan P. Jackson

Use of botanical-based dietary supplements is increasing among people of all ages and in most geographies. Most of these populations have ready acc...

Extra funding for strategic move into downstream formulation and fill finish capabilities and full exploitation of Lock-Release as new ADC manufact...

New premises at Milton Park, Oxfordshire, UK and in Boston, MA support rapid expansion of company

Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery s...

Thermo Scientific Mass Frontier 8.0 software with Thermo Scientific Orbitrap ID-X Tribrid Mass Spectrometer streamlines small-molecule unknown comp...

Plasticell receives EU funding as part of €3.7 million consortium to advance neurodegenerative disease research

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

Dates: 4-8 November 2018
Venue: Washington DC, USA

Dates: 2-6 February 2019
Venue: Washington DC, USA

Dates: 27-28 February 2019
Venue: Oxford, UK

Dates: 29 March - 3 April 2019
Venue: Atlanta, USA

Dates: 1-2 April 2019
Venue: Coronado Island, USA

Dates: 2-3 April 2019
Venue: Cambridge, UK